Difference between revisions of "Programmed cell death 1"
Jump to navigation
Jump to search
| Line 3: | Line 3: | ||
It is also known as '''CD279'''. | It is also known as '''CD279'''. | ||
PD1 binds with [[programmed death-ligand 1]] (dealt with separately) and ''programmed death-ligand 2''.<ref name=pmid22658126/> | |||
==Background== | |||
Cytotoxic T cell activation is driven by three sets of receptors:<ref name=pmid22658126>{{Cite journal | last1 = Ribas | first1 = A. | title = Tumor immunotherapy directed at PD-1. | journal = N Engl J Med | volume = 366 | issue = 26 | pages = 2517-9 | month = Jun | year = 2012 | doi = 10.1056/NEJMe1205943 | PMID = 22658126 }}</ref> | |||
{| class="wikitable sortable" | |||
! Pairings | |||
! Tumour cell | |||
! T cell | |||
|- | |||
| Antigen presenting | |||
| MHC | |||
| TCR | |||
|- | |||
| Inhibitory signal | |||
| [[PD-1]] | |||
| PD-L1 (CD274), PD-L2 (CD273) | |||
|} | |||
==Drugs== | ==Drugs== | ||
Revision as of 02:38, 12 May 2016
Programmed cell death 1, abbreviated PDCD1 and PD1,[1] is a protein (and gene) with an important role in immune system regulation and cancer. It is found on the T lymphocytes.
It is also known as CD279.
PD1 binds with programmed death-ligand 1 (dealt with separately) and programmed death-ligand 2.[2]
Background
Cytotoxic T cell activation is driven by three sets of receptors:[2]
| Pairings | Tumour cell | T cell |
|---|---|---|
| Antigen presenting | MHC | TCR |
| Inhibitory signal | PD-1 | PD-L1 (CD274), PD-L2 (CD273) |
Drugs
- Pembrolizumab.
- Nivolumab.
- Pidilizumab.
See also
- Programmed death-ligand 1 (PD-L1).
References
- ↑ Online 'Mendelian Inheritance in Man' (OMIM) 600244
- ↑ 2.0 2.1 Ribas, A. (Jun 2012). "Tumor immunotherapy directed at PD-1.". N Engl J Med 366 (26): 2517-9. doi:10.1056/NEJMe1205943. PMID 22658126.